Attention Business Editors:
Micrologix Biotech to Announce MBI 594AN Phase II Results Conference Call & Webcast Notification and Media Advisory
Friday, November 30, 2001 - 9:00 a.m. ET; 6:00 a.m. PT
Trading Symbol
TSE: MBI
US OTC: MGIXF
VANCOUVER, Nov. 29 /CNW/ - Micrologix Biotech Inc. (TSE:MBI) announced
today that it will host a conference call and webcast on Friday, November 30,
2001 to discuss the results from the Phase II clinical trial of MBI 594AN, a
novel topical drug candidate under development for the treatment of acne.
About Conference Call
Micrologix's conference call will be held on Friday, November 30, 2001 at
9:00 a.m. Eastern Time (6:00 a.m. Pacific Time). The dial in number to access
the call is: 1-888-571-5411 or 416-646-3097, reservation number 156181. A
replay of this call will be available from November 30 at 11:00 a.m. ET
through December 10, 2001. The playback number is: 1-877-289-8525, reservation
number 156181 or 416 640-1917, reservation number 156181. The Company will
retain information about accessing the call on its website at
mbiotech.com through the playback period. The call will also be
webcast in live and archived versions from Micrologix's website at
www.mbiotech.com.
About Micrologix
Micrologix Biotech Inc. is a biotechnology company engaged in the
research, development and commercialization of innovative drugs to treat or
prevent various infectious diseases. The Company's current portfolio of anti-
infective drug candidates is based on improved analogs of naturally occurring
cationic peptides found in the host defense systems of most life forms.
Micrologix currently has two drugs in clinical trials in the United States:
MBI 226 for preventing catheter-related bloodstream infections (Phase III) and
MBI 594AN for treating acne (Phase II). The Company's common shares are
included in the TSE 300 Composite Index.
-30-
For further information: Investor & Media Relations Contacts: Jonathan
Burke, Micrologix Biotech Inc., Telephone: (604) 221-9666, Toll-Free:
1-800-665-1968, E-mail: jburke@mbiotech.com; Marla Gale, Fleishman-Hillard
Canada Inc., Telephone: (416) 214-0701, Fax: (416) 214-0720, E-mail:
galem@fleishman.com; Website www.mbiotech.com |
